key: cord-0921361-5asv4xkh
authors: Stumpf, Julian; Tonnus, Wulf; Paliege, Alexander; Rettig, Ronny; Steglich, Anne; Gembardt, Florian; Kessel, Friederike; Kröger, Hannah; Arndt, Patrick; Sradnick, Jan; Frank, Kerstin; Tonn, Torsten; Hugo, Christian
title: Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant
date: 2021-07-22
journal: Transplantation
DOI: 10.1097/tp.0000000000003903
sha: 3611679777ae67d3b8b8a20e945ba11e463544ee
doc_id: 921361
cord_uid: 5asv4xkh

Supplemental Digital Content is available in the text.

K idney transplant recipients (KTRs) have an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mortality 1 and a markedly decreased immune response after 2 doses of mRNA vaccination. 2 The optimal vaccination strategy for KTRs without sufficient immune response after standard vaccination protocols remains unknown. Here, we report combined cellular and humoral response rates after a third dose of the BNT162b2 mRNA vaccine (Tozinameran; Pfizer-BioNTech COVID-19 vaccine).

In this single-center study (subanalysis of the DIA-Vacc cohort 3 ), we reported KTRs' response rates after the first (T1), second (T2), and third (T3) dose of BNT162b2 vaccination. Seventy-one KTRs (mean age ± SD, 57 ± 14.4 y, 63% men) received first and second vaccinations with BNT162b2 at a 3-wk interval. Fortyeight KTRs with insufficient humoral response after 2 vaccinations received the third dose of BNT162b2 vaccine 68 ± 1 d after the second vaccination. Immune responses to the third vaccination were assessed 4 wk after application (T3; Figure 1A ). Humoral response was determined using immunoglobulin (Ig) A and IgG antibody ELISAs against spike S1 protein and IgG ELISA against the receptor-binding domain (RBD). To exclude SARS-CoV-2 contact before or after vaccination, IgG antibodies against the nucleocapsid protein subunit were analyzed in parallel.

Causes of end-stage renal disease were glomerulonephritis in 27%; hypertensive, diabetic, or vascular disease in 18%; cystic kidney disease in 13%; vasculitis in 3%; and unknown cause in ~39% of cases. Immunosuppressive therapy included a calcineurin inhibitor in 87%, mycophenolic acid in 73%, or a mechanistic target of rapamycin inhibitor in 24%, while only 38% of KTRs had glucocorticosteroids as maintenance immunosuppression. The median time after transplantation was 7.5 ± 6 y.

Cumulative humoral response rates in all 71 KTRs were 6% (T1), 32% (T2), and 55% (T3; Figure 1B ). Cellular response was 11% at T1 (n = 7/63 patients, no T1 results were reported for 8 patients) and 34% at T2 (n = 23/68 patients, no T2 results were reported for 3 patients; Figure 1B ). At T3, cellular response was present in 26% (n = 9/35 patients, no T3 results were reported for 13 patients) and 40% showed a total humoral response ( Figure 1C ). Among the patients with a humoral response, frequencies of RBD antibodies increased to 94% after the third vaccination (T3; n = 15/16 patients) compared with 56% at T2 (n = 10/18 patients; Figure 1C ; additional accurate ELISA/interferon-γ release assay readings; Figure 1D -F).

The humoral response rates after a third mRNA vaccination to SARS-CoV-2 reported here are consistent with a recent publication by Kamar et al. 4 We demonstrate that not only the humoral but also the cellular vaccination response rates to a third dose in primary nonresponders are at least comparable with de novo responses after 2 vaccinations. The frequency of neutralizing RBD antibody responses even seemed to be improved. These data do not support the concept of T-cell exhaustion after 2 vaccinations due to high antigen presentation as previously described for viral infections including SARS-CoV-2. 4, 5 In our view, adapted vaccination protocols with additional vaccinations or higher vaccine doses in KTRs taking immunosuppressants should be encouraged and further investigated.

ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Negative clinical evolution in COVID-19 patients is frequently accompanied with an increased proportion of undifferentiated Th cells and a strong underrepresentation of the Th1 subset

The authors acknowledge DIA-Vacc Investigators. EUROIMMUN Medizinische Labordiagnostika AG, Lubeck, Germany provided antibody ELISAs and interferon-gamma release assays for this study.